Insperity (NSP) Earnings Analysis
Insperity (NSP) next reports earnings on 2026-07-29, consensus EPS 0.33 USD. Last quarter (2026-04-30) it beat with EPS 1.31 USD vs 1.24 USD est (+5.6%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E -72.79.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does NSP next report earnings?
| Next earnings date | 2026-07-29 |
|---|---|
| Consensus EPS estimate | 0.33 USD |
| Revenue estimate | 1.67B |
NSP earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | 1.31 USD | 1.24 USD | +5.6% | Beat |
| 2025-11-03 | -0.2 USD | 0.22 USD | -190.9% | Miss |
| 2025-08-01 | 0.26 USD | 0.41 USD | -36.6% | Miss |
| 2025-02-10 | 0.05 USD | 0.02 USD | +150% | Beat |
| 2024-10-31 | 0.39 USD | 0.32 USD | +21.9% | Beat |
| 2024-08-01 | 0.86 USD | 0.73 USD | +17.8% | Beat |
Beat rate: 4/6 (67%) over reported quarters with consensus data.
NSP valuation and analyst view
| Trailing P/E | -72.79 |
|---|---|
| Trailing EPS | -0.66313 USD |
| Price / book | 27.44 |
| Dividend yield | 4.92% |
| Market cap | 1.87B |
| Analyst consensus | Hold (3 buy / 4 hold / 1 sell) |
| Avg price target | 53 USD |
Related research pages
Frequently asked questions
When is Insperity (NSP)'s next earnings date?
Insperity is next scheduled to report on 2026-07-29, with a consensus EPS estimate of 0.33 USD and revenue estimate of 1.67B.
Did NSP beat earnings last quarter?
In its 2026-04-30 report, NSP posted EPS of 1.31 USD versus a 1.24 USD estimate — a beat of 5.6%.
What is NSP's earnings track record?
Over the last 6 reported quarters with consensus data, NSP beat estimates 4 times (67%).
What is NSP's current P/E ratio and EPS?
NSP trades at a trailing P/E of -72.79 on trailing EPS of -0.6631299734748011 USD.
What do analysts rate NSP?
Analyst consensus is "Hold" across 8 ratings (0 strong buy, 3 buy, 4 hold, 1 sell, 0 strong sell). Average 12-month price target: 53 USD.